WuXi XDC Cayman Inc. (L74.F)
| Previous Close | 1.9500 |
| Open | 1.9900 |
| Bid | 2.0000 x N/A |
| Ask | 2.2400 x N/A |
| Day's Range | 1.9900 - 2.0200 |
| 52 Week Range | 1.4500 - 3.8400 |
| Volume | |
| Avg. Volume | 82 |
| Market Cap | 2.59B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones
WuXi XDC Cayman Inc. ("WuXi XDC" or "the Group", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, is pleased to announce its annual results and corporate updates for the year ended 31 December 2023.
- PR Newswire
WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development
WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for ADC platform technologies, announced today that they have reached a comprehensive partnership in drug-linker technology, which is co-developed with HySlink Therapeutics ("HySlink"), and CRDMO services spanning from discovery to commercialization. WuXi XD
- PR Newswire
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)
WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company specialized in researching, developing and manufacturing innovative therapeutics that improve people's lives worldwide, announced that they have signed a Memorandum of Understanding (MOU) for comprehensive and integrated services which refer to the developmen
